ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Syndrome: Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A)
Gene/Gene Panel: F5
Context: Adult
Date
Status
Outcomes-Interventions
Notes
2020/04/28
Released
1.3.1
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 9CD
Pharmacological prophylaxis for pregnant women (GroupA) 8CB
Pharmacological prophylaxis for men and non-pregnant women (GroupA) 6CD
2020/04/28
Released (Under revision)
1.3.0
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 9CD
Pharmacological prophylaxis for pregnant women (GroupA) 8CB
Pharmacological prophylaxis for men and non-pregnant women (GroupA) 6CD
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.3.0
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 9CD
Pharmacological prophylaxis for pregnant women (GroupA) 8CB
Pharmacological prophylaxis for men and non-pregnant women (GroupA) 6CD
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.2.0
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.1.2
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
Internal system migration related to score text replacement from E to N
2018/04/09
Released
1.1.1
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
2018/04/09
Released (Under revision)
1.1.0
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
2018/03/19
Released
1.1.0
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CD
Pharmacological prophylaxis for men and non-pregnant women 6CD
Pharmacological prophylaxis for pregnant women 8CB
2018/03/19
Released (Under revision)
1.0.1
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 10CD
Pharmacological prophylaxis for men and non-pregnant women 7CD
Pharmacological prophylaxis for pregnant women 9CB
2018/01/11
Released
1.0.1
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 10CD
Pharmacological prophylaxis for men and non-pregnant women 7CD
Pharmacological prophylaxis for pregnant women 9CB
2017/10/23
Released
1.0.0
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 10CD
Pharmacological prophylaxis for men and non-pregnant women 7CD
Pharmacological prophylaxis for pregnant women 9CB
¤ Powered by BCM's Genboree.